Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical Indus is benefiting from a clear shift from a generics-led model toward branded innovation, with 3Q26 revenue of $4.395B and non-GAAP EPS of $0.86 both beating expectations while gross margin expanded to 55.5% and operating margin rose to 31.7%. The company’s core commercial engines are strengthening, as Austedo growth is supported by higher dose intensity and mandatory Part D coverage, Ajovy posted 61% constant-currency growth to $269M, and Uzedy rose 96% to $85M, while biosimilars are expected to exceed $800M in 2026. Management’s FY26 revenue guidance of $16.7B-$17.0B and margin progression into 2027 suggest that operating leverage, transformation savings, and a deep pipeline led by duvakitug and TEV-408 can sustain earnings growth despite the Austedo pricing reset.

Teva Pharmaceutical Indus is viewed negatively because its growth engine depends on several assumptions that may not hold: AUSTEDO must keep share through 2029, generics and biosimilars must reaccelerate after the Revlimid headwind, and biosimilar revenue must double by 2027. Its innovative pipeline also looks fragile, as olanzapine LAI depends on a PDSS-free label and duvakitug would need successful Phase 3 execution in 2025 to justify meaningful contribution, while competitive pressure from Merck and Roche raises the bar. On top of that, material opioid, price-fixing, and environmental contingencies could divert cash from deleveraging, and generic pricing volatility may compress margins and limit funding for innovation.